Navigation Links
ViroDefense Inc Announces Selection of Poliovirus Antiviral Preclinical Candidate
Date:6/3/2008

Compound Emerged from Technology Licensed from Schering-Plough Research

Institute

ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- ViroDefense Inc today announced that it has chosen to advance a compound licensed to ViroDefense Inc by Schering-Plough Corporation into IND-enabling preclinical studies for the prevention and treatment of poliovirus infections.

Schering-Plough licensed to ViroDefense Inc the exclusive rights for development of a specific compound series for polio indications. The license was provided in exchange for the purchase of compound testing supplies and potential future royalties on sales. Schering-Plough Research Institute had been developing the series for treatment of diseases caused by non-polio enteroviruses, such as the coxsackie viruses. ViroDefense Inc determined in laboratory tests that compounds of the series had promising anti-poliovirus activity.

The licensed compounds belong to the antiviral mechanistic class termed "capsid inhibitors." Compounds of this class inhibit the function of the poliovirus capsid, the outer protein coat of the virus, by integrating into the capsid at a specific site or pocket. By doing so, they prevent virus "uncoating" and the release of the viral RNA from the capsid, thereby blocking the initiation of the viral infection cycle.

The lead anti-poliovirus compound, V-073, has been shown to have potent and broad-spectrum anti-poliovirus specific activity, favorable pharmacologic and pharmacokinetic attributes, and the safety and tolerability profile suitable for its advancement as a preclinical candidate. Consequently, IND- enabling studies will commence with V-073.

"We are grateful to Schering-Plough for their willingness to offer this promising antiviral series for the fight against polio," commented Marc S. Collett, President of ViroDefense Inc. "This is clearly a humanitarian gesture on their part."

"We are very pleased to support ViroDefense in its efforts to address a clear public health need during both the final stages of the polio eradication effort and in the post-eradication era," said Thomas P. Koestler, Ph.D., President of Schering-Plough Research Institute.

Background

The Global Polio Eradication Initiative, launched by the World Health Organization (WHO) in 1988, is approaching its goal and expects to certify the world free of polio in the near future. Protecting the estimated $7 billion, two-decade investment will depend on the policies, defense strategies and emergency response capabilities available during these final stages of eradication and in the post-eradication era. These safeguards must protect against virus re-introduction, and in the event of re-introduction, must rapidly contain, control and eliminate the virus.

In November 2005, the National Research Council (NRC) held a workshop, at the request of the World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC), to discuss the role and utility of a polio antiviral drug in the efforts to eradicate poliovirus and in the defense of a polio-free world post-eradication. It was concluded that a polio antiviral drug, used alone or in conjunction with current vaccines, would be useful in the control of polio outbreaks, providing increased response flexibility and improved effectiveness. It was further recommended that drug development begin immediately. Currently, there are no drugs for treatment or prevention of poliovirus disease.

In October 2006, the Task Force for Child Survival and Development proposed that a Poliovirus Antiviral Initiative be established to implement the NRC recommendations. The Advisory Committee on Poliomyelitis Eradication (ACPE) supported the proposal and recommended action. In June 2007, the CDC acted on the ACPE recommendations by contracting the Task Force to facilitate development of effective polio antiviral drugs for global public health applications.

About ViroDefense Inc

ViroDefense Inc is an antiviral research, development and consulting company that advocates for and facilitates development of effective antiviral pharmaceuticals that address global public health threats. ViroDefense Inc is presently focused on development of antiviral drugs for poliomyelitis. Currently, there are no poliovirus antiviral drug products available. ViroDefense INC has offices in the Rockville Innovation Center, located in Rockville, MD, part of the Montgomery County Department of Economic Development's Business Innovation Network.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.


'/>"/>
SOURCE ViroDefense Inc
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. BioElectronics Announces Profitability Breakeven and Additional Clinical Trials
2. Anesiva Announces South Korea FDA Approval of Adlea(TM) Investigational New Drug Application
3. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
4. Trubion Announces Presentation of Positive TRU-016 Data at ASCO
5. Alliance Pharmaceutical Corp. Announces Approval of Proposed Actions at Annual Shareholders Meeting
6. Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
7. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
8. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
9. IDM Pharma Announces Phase 2 Follow-Up Data Showing IDM-2101 is Well Tolerated With Positive Survival Trend in Non-Small Cell Lung Cancer Patients
10. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
11. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided ... Piedras, Puerto Rico , where the ... Following a comprehensive onsite ... structural damage, temporary loss of power and minimal water ... manufacturing operations have resumed, and the company expects to ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The International ... promote standards of excellence for the field of eating disorders, announces the opening ... 25, 2018 in Orlando, Florida at the Omni Resort at ChampionsGate. ...
(Date:10/13/2017)... ... ... Lori R. Somekh, founder of the Law Office of Somekh & ... and special needs planning attorneys. “Membership in ElderCounsel helps our office remain up to ... with elder law attorneys nationwide,” said Somekh. , ElderCounsel was founded ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
Breaking Medicine News(10 mins):